PCSK9 inhibition in heart failure Do PCSK9 inhibitors have a role in sepsis?RACING trial: Do we need to rethink LDL-lowering strategies in Asian high-risk patients?A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease More reassurance on the safety of PCSK9 inhibitors

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Question of the Month

What’s new on the horizon for lipoprotein(a) therapies?

Prof Henry Ginsberg (Columbia University, New York, USA) overviews the latest news in novel Lp(a) therapies.
Watch video »

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

News from the Trials

Keep up to date with latest news and analyses from PCSK9 inhibitor trials.

View latest news »

Trial Resources

For expert analysis and insights

View Trials »

View Trial slide decks »

Most viewed

LAPLACE-TIMI 57 LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH? ORION-5 ODYSSEY-KT: Alirocumab shows benefit in trial in S. Korea and Taiwan Cholesterol crystals, plaque stability and ASCVD RACING trial: Do we need to rethink LDL-lowering strategies in Asian high-risk patients?

Most viewed

LAPLACE-TIMI 57

Hot Topics

16th Virtual Closed Scientific Expert Meeting of the Editorial Board
Statin intolerance: Do we need a new clinical definition and management strategies?

Professor Ulrich Laufs provides a European perspective to this question.

Watch now

Professor Paul Thompson gives a US perspective to what is needed for research into statin intolerance and statin-associated muscle symptoms.

Watch now

From the Editors

Reducing residual risk: Are cholesterol crystals the next target?

Prof John Chapman Pitié-Salpetrière University Hospital, INSERM, Paris France discusses how cholesterol crystals play a crucial role in atherothrombosis, and potential therapeutic options.